Ainos, Inc. (NASDAQ:AIMD) reported third-quarter 2026 revenue of $642,889, an increase of 29,567% from the corresponding period last year, supported by licensing income from its VELDONA programme and commercial activity involving its AI Nose semiconductor technology.
For the quarter ended September 30, 2026, the company reported a 36% year-on-year reduction in its GAAP net loss, while its adjusted net loss decreased 51%.
Ainos also reported a GAAP gross margin of 83.4%, compared with 78.0% in the third quarter of 2025. Operating expenses declined 20.3% over the same period.
The results included recognition of a one-time $600,000 VELDONA licensing fee, alongside revenue generated from AI Nose semiconductor agreements.
During the third quarter, Ainos delivered 1,400 AI Nose systems to an existing semiconductor customer under an initial three-year agreement valued at $2.1 million.
The company expects the agreement to generate approximately $175,000 in recurring quarterly revenue beginning in the fourth quarter of 2026.
Ainos also received initial orders from another semiconductor customer during the reporting period.
Following quarter-end, its existing backend semiconductor customer signed an additional $9 million purchase agreement covering 5,000 AI Nose systems.
Under the agreement, an initial payment of $4.5 million is due within 60 days of signing, with the remaining balance payable following completion and delivery of the equipment.
The company said the new order represents an expansion of its existing commercial relationship.
Ainos completed a technology transfer under its VELDONA licensing programme during the third quarter, triggering recognition of an initial $600,000 licensing fee.
The payment was subsequently collected after the reporting period.
The company has also established a potential licensing framework valued at up to $10 million, covering two initial therapeutic indications and additional opportunities subject to specified conditions.
Under the proposed arrangements, the licensing partner would finance assigned clinical and regulatory development activities, while Ainos would retain ownership of its underlying technology platform and participation in applicable net sublicensing revenue.
The potential $10 million value remains conditional and does not represent revenue already recognised.
Ainos reported a GAAP gross margin of 83.4% for the third quarter, up from 78.0% a year earlier.
Its non-GAAP gross margin increased to 83.6% from 78.0%, excluding specified share-based compensation, depreciation and amortisation expenses allocated to cost of revenue.
GAAP operating expenses declined 20.3% year on year, contributing to the reduction in the company’s net loss.
Chief Financial Officer Christopher Lee commented on the results.
“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%,” Lee said.
The company defines adjusted net loss as its GAAP net loss excluding share-based compensation, depreciation and amortisation, and common stock issued as a special stock bonus. The measure is not equivalent to EBITDA.
Ainos continued developing its AI Nose technology during the quarter, introducing a second-generation system with hardware and software updates designed for continuous chemical sensing in industrial environments.
The company also received three Japanese patents covering AI Nose technologies and their integration with robotic systems.
Its chemical dataset exceeded one billion records in September before increasing to more than three billion by October 30.
Ainos said the additional data would support product development and application-specific validation.
The company also introduced Atmosphere Engine, a modular platform designed to generate nitrogen and oxygen from ambient air near the point of use for semiconductor manufacturing and artificial intelligence infrastructure applications.
Ainos reported collecting $950,000 in contractual payments after September 30, associated with VELDONA licensing and AI Nose semiconductor commercialisation.
The company also began discussions concerning convertible notes scheduled to mature in 2027.
Management said the additional AI Nose agreement and expected contractual payments could support working capital as the company fulfils existing orders.
Eddy Tsai, Chairman, President and Chief Executive Officer, commented on the company’s commercial developments.
“Following quarter-end, our existing backend semiconductor customer signed a $9 million purchase agreement for 5,000 additional AI Nose systems—more than four times the value of the initial agreement,” Tsai said.
The company’s near-term priorities include delivering the additional AI Nose systems, expanding recurring service revenue, progressing VELDONA licensing arrangements and managing its financing obligations.
Future revenue growth will depend partly on contract execution, customer payments and the expansion of its semiconductor technology business.
Ainos stock price
| 11 hours | |
| 13 hours | |
| Nov-12 | |
| Oct-30 | |
| Sep-30 | |
| Sep-29 | |
| Sep-28 | |
| Sep-24 | |
| Sep-16 | |
| Sep-14 | |
| Sep-14 | |
| Sep-09 | |
| Aug-19 | |
| Aug-17 | |
| Aug-13 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite